- Home
- GTX vs RCUS Comparison
GTX vs RCUS Comparison
Compare GTX & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTX | RCUS |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GTX | RCUS |
|---|---|---|
| Price | $19.03 | $23.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $20.40 | ★ $30.27 |
| AVG Volume (30 Days) | ★ 1.7M | 817.7K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 20.63 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $3,584,000,000.00 | $247,000,000.00 |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $3.57 | $83.23 |
| P/E Ratio | $12.68 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $8.77 | $7.06 |
| 52 Week High | $21.42 | $26.40 |
Technical Indicators
Market Signals| Indicator | GTX | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 58.66 |
| Support Level | $17.70 | $20.18 |
| Resistance Level | $19.28 | $24.33 |
| Average True Range (ATR) | 0.46 | 1.08 |
| MACD | 0.16 | 0.16 |
| Stochastic Oscillator | 72.97 | 94.32 |
Price Performance
Historical ComparisonAbout GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.